Berenberg Bank analyst Berenberg Bank maintained a Buy rating on Zurich Insurance Group (ZFSVF – Research Report) on February 13 and set a price target of CHF515.90. The company’s shares closed last Monday at $468.61.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zurich Insurance Group with a $516.64 average price target, which is a 5.9% upside from current levels. In a report issued on February 6, Morgan Stanley also upgraded the stock to Buy with a CHF525.00 price target.
Zurich Insurance Group’s market cap is currently $71.21B and has a P/E ratio of 13.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zurich Insurance Group AG is a holding company, which engages in the provision of insurance products and related services. It operates through the following segments: Property and Casualty Regions, Life Regions, Farmers, Group Functions and Operations, and Non-Core Businesses. The Property and Casualty Regions segment provides motor, home and commercial products and services for individuals, as well as small and large businesses on both a local and global basis. The Life Regions segment refers to the comprehensive range of life and health insurance products on both an individual and a group basis, including annuities, endowment and term insurance, unit-linked and investment-oriented products, as well as full private health, supplemental health and long-term care insurance. The Farmers segment includes non-claims administrative and management services to the Farmers Exchanges, which are owned by policyholders. The Group Functions and Operations segment comprises the Group´s Holding and Financing and Headquarters activities. The Non-Core Businesses segment includes insurance and reinsurance businesses that the Group does not consider core to its operations and that are therefore mostly managed to achieve a beneficial run-off. The company was founded in 1872 and is headquartered in Zurich, Switzerland.
Read More on ZFSVF:
- Berenberg Bank Thinks Zebra Tech’s Stock is Going to Recover
- Leerink Partners Thinks Hookipa Pharma’s Stock is Going to Recover
- Leerink Partners Keeps Their Buy Rating on Compass Therapeutics (CMPX)
- Viracta Therapeutics (VIRX) Receives a Buy from Leerink Partners
- Leerink Partners Thinks Elevation Oncology’s Stock is Going to Recover